392 related articles for article (PubMed ID: 22341439)
1. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
Singh A; Sweeney MF; Yu M; Burger A; Greninger P; Benes C; Haber DA; Settleman J
Cell; 2012 Feb; 148(4):639-50. PubMed ID: 22341439
[TBL] [Abstract][Full Text] [Related]
2. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.
McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A
Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
4. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
[TBL] [Abstract][Full Text] [Related]
5. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
[TBL] [Abstract][Full Text] [Related]
6. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
Luo J; Emanuele MJ; Li D; Creighton CJ; Schlabach MR; Westbrook TF; Wong KK; Elledge SJ
Cell; 2009 May; 137(5):835-48. PubMed ID: 19490893
[TBL] [Abstract][Full Text] [Related]
7. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
8. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
9. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
11. Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid-inducible kinase 1.
Dehner M; Hadjihannas M; Weiske J; Huber O; Behrens J
J Biol Chem; 2008 Jul; 283(28):19201-10. PubMed ID: 18487207
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.
Obrador-Hevia A; Chin SF; González S; Rees J; Vilardell F; Greenson JK; Cordero D; Moreno V; Caldas C; Capellá G
J Pathol; 2010 May; 221(1):57-67. PubMed ID: 20196079
[TBL] [Abstract][Full Text] [Related]
13. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells.
Voloshanenko O; Erdmann G; Dubash TD; Augustin I; Metzig M; Moffa G; Hundsrucker C; Kerr G; Sandmann T; Anchang B; Demir K; Boehm C; Leible S; Ball CR; Glimm H; Spang R; Boutros M
Nat Commun; 2013; 4():2610. PubMed ID: 24162018
[TBL] [Abstract][Full Text] [Related]
14. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.
Martin ES; Belmont PJ; Sinnamon MJ; Richard LG; Yuan J; Coffee EM; Roper J; Lee L; Heidari P; Lunt SY; Goel G; Ji X; Xie Z; Xie T; Lamb J; Weinrich SL; VanArsdale T; Bronson RT; Xavier RJ; Vander Heiden MG; Kan JL; Mahmood U; Hung KE
Clin Cancer Res; 2013 Jun; 19(11):2929-40. PubMed ID: 23403635
[TBL] [Abstract][Full Text] [Related]
15. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
[TBL] [Abstract][Full Text] [Related]
16. KRAS and YAP1 converge to regulate EMT and tumor survival.
Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
[TBL] [Abstract][Full Text] [Related]
17. Wnt and Kras signaling-dark siblings in lung cancer.
Pacheco-Pinedo EC; Morrisey EE
Oncotarget; 2011 Jul; 2(7):569-74. PubMed ID: 21753228
[TBL] [Abstract][Full Text] [Related]
18. Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells.
Hrabe JE; O'Leary BR; Fath MA; Rodman SN; Button AM; Domann FE; Spitz DR; Mezhir JJ
Redox Biol; 2015 Aug; 5():319-327. PubMed ID: 26114584
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C; Fröhling S; Dunn IF; Schinzel AC; Barbie DA; Kim SY; Silver SJ; Tamayo P; Wadlow RC; Ramaswamy S; Döhner K; Bullinger L; Sandy P; Boehm JS; Root DE; Jacks T; Hahn WC; Gilliland DG
Cell; 2009 May; 137(5):821-34. PubMed ID: 19490892
[TBL] [Abstract][Full Text] [Related]
20. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
